Misc

Question 1

BRAF mutation status is of paramount importance in patients with?

Answer 1

melanoma

Question 2

RAS mutation status is relevant to the use of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in?

Answer 2

colorectal cancer

Question 3

The International Late Effects of Childhood Cancer Guideline Harmonization Group recommends that for women who received chest wall radiation before the age of 30 years, breast screening should begin at?

Answer 3

age 25 years or 8 years after completion of radiation therapy, whichever is last

Question 4

Olaparib is approved for use to treat?

Answer 4

relapsed ovarian cancer in women with BRCA1 or BRCA2 germline mutations.
- also approved for maintenance therapy for patients with BRCA1 or BRCA2 mutations with a complete or partial remission after first-line platinum-based chemotherapy. However, it is not used as initial therapy in ovarian cancer.

Question 5

Well-differentiated, low-grade, metastatic gastrointestinal neuroendocrine tumors are often indolent and asymptomatic and require what surveillance?

Answer 5

do not require immediate treatment; repeat CT scan in 3 months

Question 6

Patients with widely metastatic HR+, HER2 neg, breast cancer can benefit from what type of therapy?

Answer 6

combination antiestrogen therapy (e.g., aromatase inhibitors like anastrozole, letrozole, exemestane) + palbociclib

Question 7

Acute promyelocytic leukemia may present with?

Answer 7

a reduced total leukocyte count and features of disseminated intravascular coagulation

Question 8

What treatment is recommended to decrease breast cancer recurrence in women with high-risk, early-stage, hormone receptor–positive breast cancer who remain premenopausal after chemotherapy?

Answer 8

Ovarian suppression along with antiestrogen therapy –> leuprolide + aromatase inhibitor

Question 9

treatment of localized gastroesophageal cancer?

Answer 9

neoadjuvant chemotherapy plus radiation therapy before a planned curative-intent surgery